EGFR and non-small cell lung carcinoma: In EGFR-mutant NSCLC patients with intrathoracic disease (M0/M1a) or cases with low copy T790M, the positive rate was 63.6% (N = 7/11) and 45.5% (N = 5/11) in short-length exoTNA and cfDNA, respectively (Fig. 2b).